Insulin Delivery Devices Market To Reach US$ 33.1 Billion By 2033

The global insulin delivery devices market is poised to expand at 7% CAGR during the forecast period (2023 to 2033). Worldwide insulin delivery device sales are expected to reach US$ 16.8 billion in 2023.

Demand for insulin delivery devices is anticipated to skyrocket by nearly 2x by the end of 2033. It is attributed to the increasing prevalence of diabetes globally. Backed by this, overall sales in the market would surpass US$ 33.1 billion by the end of 2033.

A couple of key factors driving development in the market include increasing cases of obesity and the adoption of sedentary lifestyles. Innovations in insulin delivery device technology and the presence of favorable reimbursement policies would also fuel sales. Increasing awareness about diabetes management would further ensure development in the market.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=5105?PS

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬:

• The insulin delivery devices market would surge at a CAGR of 7% during the forecast period.
• Based on product type, insulin pens would witness an uptick with a 35% of market share by 2023.
• By 2033, the global insulin delivery devices market is expected to surpass US$ 33.1 billion.
• North America insulin delivery devices market share was 36% in 2022.
• China insulin delivery devices market would surge at a CAGR of 9.1% over the forecast period.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

Increasing use of portable insulin delivery devices at home to save on clinic visiting costs, waiting time, and hospital fee would drive sales.

Rising smoking habits and changing food consumption patterns might lead to type 2 diabetes, which would push demand for advanced devices.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=5105?PS

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐛𝐲 𝐅𝐚𝐜𝐭.𝐌𝐑

• Becton, Dickinson, and Company
• SOOIL Development Co. Ltd.
• F. Hoffmann- La Roche Ltd.
• Owen Mumford Ltd.
• Insulet Corporation
• Sanofi S.A.
• Mannkind Corporation
• Ypsomed Holding AG
• B. Braun Melsungen AG
• Novo Nordisk A/S
• Valeritas Inc.
• Eli Lily and Company
• Biocon Ltd.
• CellNova Group SA
• Medtronic plc
• Tandem Diabetes Care Inc

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

Key manufacturers are acquiring local companies specializing in research and development activities. They are aiming to develop new technologies.

They are also aiming for mergers, acquisitions, partnerships, product developments, and launches. They are doing so to gain a competitive edge in the insulin delivery devices market.

𝐅𝐨𝐫 𝐢𝐧𝐬𝐭𝐚𝐧𝐜𝐞,

In May 2022, Roche Diabetes Care announced the launch of ACCU-FINE. It is a high-quality pen needle. It makes insulin injections less painful and smooth for diabetics.

In April 2022, Abbott collaborated with CamDiab and Ypsomed to bring an artificial pancreas system to Europe. Blood sugar levels will be put into a mobile app developed by CamDiab. It will also be available in a smart insulin pump launched by Ypsomed.

𝐌𝐨𝐫𝐞 𝐕𝐚𝐥𝐮𝐚𝐛𝐥𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐃𝐞𝐯𝐢𝐜𝐞𝐬

In the up-to-date study, Fact.MR provides an unbiased analysis of the global insulin delivery devices market during the forecast period (2023 to 2033). The survey also offers a comprehensive analysis of the key trends, opportunities, and drivers propelling the sales of insulin delivery devices through detailed segmentation as follows:

Product Type:

Insulin Pens
Insulin Syringes
Insulin Pumps
Others

Distribution Channel:

Online Sales
Retail Pharmacies
Hospital Pharmacies
Diabetes Clinic/Centers

Regions:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

𝐊𝐞𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐑𝐞𝐩𝐨𝐫𝐭

• How will the demand for insulin delivery devices surge during the forecast period?
• Which are the key trends propelling the sales of insulin delivery devices in the market?
• Which region will be the most lucrative in the insulin delivery devices market from 2023 to 2033?
• What is the projected market valuation of the insulin delivery devices market in 2033?
• What are the challenges insulin delivery device providers might face over the upcoming decade?

Contact:

Us Sales Office :
11140 Rockville Pike
Suite 400
Rockville, Md 20852
United States
Tel: +1 (628) 251-1583

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.